Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Authors:
- Nakul M. ShahNSNakul M. Shah
- Beatriz Alvarado-HernandezBABeatriz Alvarado-Hernandez
- Xinyue ChenXCXinyue Chen
- Quentin KimanaQKQuentin Kimana
- Felicity NamayanjaFNFelicity Namayanja
- Wei LuWLWei Lu
- Khaja B. KhanKKKhaja B. Khan
- Robert J. AlatrashRARobert J. Alatrash
- Juan J. GallegosJGJuan J. Gallegos
- Jun YanJYJun Yan
- Chunhua ShiCSChunhua Shi
- Patient Mosaic TeamPTPatient Mosaic Team
- 18 August 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4945-4955
Abstract
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design: To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results: This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions: Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.Keywords
All Related Versions
Funding Information
- Cancer Prevention and Research Institute of Texas (RR220009)
This publication has 68 references indexed in Scilit:
- fastp 1.0: An ultra‐fast all‐round tool for FASTQ data quality control and preprocessingiMeta, 2025
- Spatial heterogeneity of FGFR2b in gastric cancer: a comparative analysis of primary tumors and peritoneal disseminationVirchows Archiv, 2025
- HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironmentJournal of Cancer Research and Clinical Oncology, 2024
- Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological studyVirchows Archiv, 2024
- Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialGastric Cancer, 2024
- 384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)Annals of Oncology, 2022
- FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic AlterationsDigestive Diseases and Sciences, 2021
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular ProfilesCell Reports, 2017
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Isoforms of Receptors of Fibroblast Growth FactorsJournal of Cellular Physiology, 2014